Background The 2009 influenza A （H1N1） virus infection is associated with the high risk of severe complications and is spreading more rapidly throughout the world than other reported seasonal influenzas. This study ...Background The 2009 influenza A （H1N1） virus infection is associated with the high risk of severe complications and is spreading more rapidly throughout the world than other reported seasonal influenzas. This study aimed to evaluate the efficacy and safety of the nature herbal medicine Lianhuaqingwen capsule （LHC） in patients infected with influenza A （H1N1） virus. Methods A total of 244 patients aged 16-65 years confirmed with influenza A （H1N1） virus infection by the real time RT-PCR were randomized to one of two treatment groups of 122 patients each. Each group assigned to receive either LHC or Oseltamivir for five days and observation for seven days. The patients were enrolled within 36 hours of illness onset if they had an axillary temperature of ≥37.4℃ and with at least one of the following symptoms： nasal obstruction, runny nose, cough, sore throat, fatigue, headache, myalgia, chills and sweating. The primary end point was the duration of illness. Results Of 244 patients, 240 （98.36%） patients with a median age 21 years completed the study between October 24, 2009 and November 23, 2009. There were no significant overall differences between LHC treated and Oseltamivir treated patients in the median duration of illness （LHC 69 hours vs. Oseltamivir 85 hours P 〉0.05） or the median duration of viral shedding （LHC 103 hours vs. Oseltamivir 96 hours, P 〉0.05）. However, it was worthwhile to note that LHC significantly reduced the severity of illness and the duration of symptoms including fever, cough, sore throat, and fatigue （P〈0.05）. Both study medications were well tolerated. No drug related serious adverse events occurred during the study. Conclusions Compared with Oseltamivir, LHC achieved a similar therapeutic effectiveness reduction of the duration of illness and duration of viral shedding. Therefore, LHC might be an alternative therapeutic measure for influenza A （H1N1） virus infections.展开更多
Houttuynia cordata polysaccharide(HCP) is extracted from Houttuynia cordata, a key traditional Chinese medicine. The study was to investigate the effects of HCP on intestinal barrier and microbiota in H1N1 virus infec...Houttuynia cordata polysaccharide(HCP) is extracted from Houttuynia cordata, a key traditional Chinese medicine. The study was to investigate the effects of HCP on intestinal barrier and microbiota in H1N1 virus infected mice. Mice were infected with H1N1 virus and orally administrated HCP at a dosage of 40 mg×kg^(–1)×d^(–1). H1N1 infection caused pulmonary and intestinal injury and gut microbiota imbalance. HCP significantly suppressed the expression of hypoxia inducible factor-1α and decreased mucosubstances in goblet cells, but restored the level of zonula occludens-1 in intestine. HCP also reversed the composition change of intestinal microbiota caused by H1N1 infection, with significantly reduced relative abundances of Vibrio and Bacillus, the pathogenic bacterial genera. Furthermore, HCP rebalanced the gut microbiota and restored the intestinal homeostasis to some degree. The inhibition of inflammation was associated with the reduced level of Toll-like receptors and interleukin-1β in intestine, as well as the increased production of interleukin-10. Oral administration of HCP alleviated lung injury and intestinal dysfunction caused by H1N1 infection. HCP may gain systemic treatment by local acting on intestine and microbiota. This study proved the high-value application of HCP.展开更多
目的:分析甲型H1N1流感(简称"甲流")患儿血常规、血清淀粉样蛋白A(serum amyloid A,SA A)及C反应蛋白(Creactiveprotein,CRP)水平,为初步诊断儿童甲流提供帮助。方法:选择138例甲流患儿(A组)、126例普通流感患儿(B组)和120名...目的:分析甲型H1N1流感(简称"甲流")患儿血常规、血清淀粉样蛋白A(serum amyloid A,SA A)及C反应蛋白(Creactiveprotein,CRP)水平,为初步诊断儿童甲流提供帮助。方法:选择138例甲流患儿(A组)、126例普通流感患儿(B组)和120名健康对照儿童(C组),统计分析白细胞(white blood cells,WBC)计数、血小板(platelet,PLT)计数、平均血小板体积(mean plateletv o l u m e, M P V)、中性粒细胞百分比、淋巴细胞百分比、单核细胞百分比以及全血S A A和C R P水平。三组间计量资料比较采用F检验,两两组间计量资料比较采用L SD检验。结果:3组W B C计数差异无统计学意义(F=2.698, P>0.05); A组PLT计数较B组和C组显著降低(F=6.598,P <0. 0 5); A组M P V水平与B, C两组相比,差异有统计学意义(F=5. 9 8 9, P <0. 0 5)。采用L S D检验进行两两组间比较:A组PLT计数显著低于B组(q=6.26,P<0.05),但与C组相比差异无统计学意义(q=3.02,P>0.05);A组MPV水平显著低于C组(q=6.23,P<0.05),B组MPV水平也显著低于C组(q=6.84,P<0.05),但A组与B组MPV水平无显著差异(q=1.06,P>0.05)。三组中性粒细胞含量、单核细胞含量、淋巴细胞含量差异均有统计学意义(F值分别为5.364,5.261,6.169,均P <0.05)。A组淋巴细胞和中性粒细胞含量与C组比较差异无统计学意义(q值分别为2.36、 1.94,均P>0.05),但A组单核细胞百分比明显高于B组和C组,差异有统计学意义(q值分别为6.29,6. 1 0,均P <0. 0 5)。A组S A A水平与B组和C组比较,差异有统计学意义(F=8. 1 9 8, P <0. 0 5)。A组与B组SAA水平差异有统计学意义(q=6.97,P<0.05);A,B两组SAA水平均显著高于C组,差异有统计学意义(q值分别为6.99、6.07,均P<0.05)。A组CRP水平与B组和C组比较,差异有统计学意义(F=7.654,P<0.05)。A组与B组间CRP水平差异无统计学意义(q=1.94,P>0.05);但A,B两组C R P水平均显著高于C组,差异有统计学意义(q值分别为6. 4 8, 6. 6 1,均P <0. 0 5)。通过RO C分析得知,SA A诊断甲展开更多
文摘Background The 2009 influenza A （H1N1） virus infection is associated with the high risk of severe complications and is spreading more rapidly throughout the world than other reported seasonal influenzas. This study aimed to evaluate the efficacy and safety of the nature herbal medicine Lianhuaqingwen capsule （LHC） in patients infected with influenza A （H1N1） virus. Methods A total of 244 patients aged 16-65 years confirmed with influenza A （H1N1） virus infection by the real time RT-PCR were randomized to one of two treatment groups of 122 patients each. Each group assigned to receive either LHC or Oseltamivir for five days and observation for seven days. The patients were enrolled within 36 hours of illness onset if they had an axillary temperature of ≥37.4℃ and with at least one of the following symptoms： nasal obstruction, runny nose, cough, sore throat, fatigue, headache, myalgia, chills and sweating. The primary end point was the duration of illness. Results Of 244 patients, 240 （98.36%） patients with a median age 21 years completed the study between October 24, 2009 and November 23, 2009. There were no significant overall differences between LHC treated and Oseltamivir treated patients in the median duration of illness （LHC 69 hours vs. Oseltamivir 85 hours P 〉0.05） or the median duration of viral shedding （LHC 103 hours vs. Oseltamivir 96 hours, P 〉0.05）. However, it was worthwhile to note that LHC significantly reduced the severity of illness and the duration of symptoms including fever, cough, sore throat, and fatigue （P〈0.05）. Both study medications were well tolerated. No drug related serious adverse events occurred during the study. Conclusions Compared with Oseltamivir, LHC achieved a similar therapeutic effectiveness reduction of the duration of illness and duration of viral shedding. Therefore, LHC might be an alternative therapeutic measure for influenza A （H1N1） virus infections.
基金supported by the National Natural Science Foundation of China(Nos.81330089,8167365881274165 and 81673713)the State Key Program for New Drugsfrom the Ministry of Science and Technology,China(No2018ZX0935003-002)
文摘Houttuynia cordata polysaccharide(HCP) is extracted from Houttuynia cordata, a key traditional Chinese medicine. The study was to investigate the effects of HCP on intestinal barrier and microbiota in H1N1 virus infected mice. Mice were infected with H1N1 virus and orally administrated HCP at a dosage of 40 mg×kg^(–1)×d^(–1). H1N1 infection caused pulmonary and intestinal injury and gut microbiota imbalance. HCP significantly suppressed the expression of hypoxia inducible factor-1α and decreased mucosubstances in goblet cells, but restored the level of zonula occludens-1 in intestine. HCP also reversed the composition change of intestinal microbiota caused by H1N1 infection, with significantly reduced relative abundances of Vibrio and Bacillus, the pathogenic bacterial genera. Furthermore, HCP rebalanced the gut microbiota and restored the intestinal homeostasis to some degree. The inhibition of inflammation was associated with the reduced level of Toll-like receptors and interleukin-1β in intestine, as well as the increased production of interleukin-10. Oral administration of HCP alleviated lung injury and intestinal dysfunction caused by H1N1 infection. HCP may gain systemic treatment by local acting on intestine and microbiota. This study proved the high-value application of HCP.
文摘目的:分析甲型H1N1流感(简称"甲流")患儿血常规、血清淀粉样蛋白A(serum amyloid A,SA A)及C反应蛋白(Creactiveprotein,CRP)水平,为初步诊断儿童甲流提供帮助。方法:选择138例甲流患儿(A组)、126例普通流感患儿(B组)和120名健康对照儿童(C组),统计分析白细胞(white blood cells,WBC)计数、血小板(platelet,PLT)计数、平均血小板体积(mean plateletv o l u m e, M P V)、中性粒细胞百分比、淋巴细胞百分比、单核细胞百分比以及全血S A A和C R P水平。三组间计量资料比较采用F检验,两两组间计量资料比较采用L SD检验。结果:3组W B C计数差异无统计学意义(F=2.698, P>0.05); A组PLT计数较B组和C组显著降低(F=6.598,P <0. 0 5); A组M P V水平与B, C两组相比,差异有统计学意义(F=5. 9 8 9, P <0. 0 5)。采用L S D检验进行两两组间比较:A组PLT计数显著低于B组(q=6.26,P<0.05),但与C组相比差异无统计学意义(q=3.02,P>0.05);A组MPV水平显著低于C组(q=6.23,P<0.05),B组MPV水平也显著低于C组(q=6.84,P<0.05),但A组与B组MPV水平无显著差异(q=1.06,P>0.05)。三组中性粒细胞含量、单核细胞含量、淋巴细胞含量差异均有统计学意义(F值分别为5.364,5.261,6.169,均P <0.05)。A组淋巴细胞和中性粒细胞含量与C组比较差异无统计学意义(q值分别为2.36、 1.94,均P>0.05),但A组单核细胞百分比明显高于B组和C组,差异有统计学意义(q值分别为6.29,6. 1 0,均P <0. 0 5)。A组S A A水平与B组和C组比较,差异有统计学意义(F=8. 1 9 8, P <0. 0 5)。A组与B组SAA水平差异有统计学意义(q=6.97,P<0.05);A,B两组SAA水平均显著高于C组,差异有统计学意义(q值分别为6.99、6.07,均P<0.05)。A组CRP水平与B组和C组比较,差异有统计学意义(F=7.654,P<0.05)。A组与B组间CRP水平差异无统计学意义(q=1.94,P>0.05);但A,B两组C R P水平均显著高于C组,差异有统计学意义(q值分别为6. 4 8, 6. 6 1,均P <0. 0 5)。通过RO C分析得知,SA A诊断甲
